7.3.1.1.2 Summary of evidence and recommendations for local therapy of advanced/metastatic RCC,
Summary of evidence,LE
Adjuvant pembrolizumab defined by the inclusion criteria of the trial* after nephrectomy   improves DFS.,1b
Adjuvant PD-L1 inhibition with atezolizumab did not improve DFS or OS.,1b
Adjuvant dual PD-1 and CTLA-4 inhibition with nivolumab and ipilimumab did not improve DFS.,1b
Peri-operative treatment with nivolumab did not improve RFS.,1b
The lack of biomarker data is hindering progress in this field. Adjuvant RCTs are ongoing to   evaluate the benefit of adjuvant immunotherapy after nephrectomy in high-risk patients.,4
